Screener
Corvus Pharmaceuticals CRVS Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40,102 | $4,576 |
| Marketable securities | 196,612 | 52,174 |
| Accounts receivable - related party | 43 | 37 |
| Prepaid and other current assets | 3,189 | 1,427 |
| Total current assets | 239,946 | 58,214 |
| Property and equipment, net | 282 | 220 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's short-term investments?
- Corvus Pharmaceuticals (CRVS) reported short-term investments of $196.61M in Q1 2026.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Corvus Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude